1. Improving Outcomes in Patients With SSc-ILD

3. Introduction

4. Overview of Major SSc Complications

5. Prevalence of ILD in Patients with SSc

6. ILD Appears Early in the Course of SSc

7. Importance of Identifying SSc-ILD Patients at Risk of Progression

8. Identification of Patients at Risk of Disease Progression Is the Key

9. Disease Progression: Definition

10. Predicting Factors for Progressive ILD

11. Screening for ILD Using HRCT and PFTs

12. How to Screen for ILD

13. FVC and HRCT to Evaluate Patients with SSc-ILD

14. Tools for Screening

15. Who to Screen?

16. Example of Algorithm Used to Determine When Treatment for SSc-ILD Should Be Initiated: University of California

17. Example of Algorithm Used to Determine When Treatment for SSc-ILD Should Be Initiated: University of California (cont)

18. Who to Treat?

19. Who to Treat (cont)

20. What Are the Treatment Goals in SSc-ILD?

21. Oral Cyclophosphamide in SSc-PF: SLS-I

22. SLS II Primary Outcome Assessment

23. ASCT for DcSSc

24. ASCT vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis

25. What Are the Unmet Needs With Current Therapies?

26. Intensity to Treat to Get Remission

27. Rituximab EUSTAR Observational Study

28. Targeted Therapies in SSc/SSc-ILD

29. SLS-III Phase 2 Trial With Pirfenidone

30. Tocilizumab: focuSSced Phase 3 Study

31. SENSCIS Phase 3 Trial With Nintedanib

32. Management of SSc-ILD

33. How to Follow Up

34. Case Presentation

35. Evolution

36. Evolution (cont)

37. Conclusions

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)